المؤلفون: André J. Tremblay, Marie-Eve Mathieu, David Thivel, Yves Boirie, Kristine Beaulieu, Vicky Drapeau, Alicia Fillon

المساهمون: Laboratoire des Adaptations Métaboliques à l'Exercice en Conditions Physiologiques et Pathologiques (AME2P), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-UFR Sciences et Techniques des Activités Physiques et Sportives - Clermont-Auvergne (UFR STAPS - UCA), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Centre de SSR Nutrition-Obésité UGECAM, University of Leeds, School of kinesiology and Physical Activity Sciences, Institute of Nutrition and Functional Foods, Université Laval [Québec] (ULaval), Unité de Nutrition Humaine (UNH), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Clermont Auvergne (UCA), Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), Mitacs Globalink grant

المصدر: British Journal of Nutrition
British Journal of Nutrition, Cambridge University Press (CUP), 2021, pp.1-28. ⟨10.1017/S0007114520002457⟩

مصطلحات موضوعية: Adult, Male, Adolescent, Hunger, 030309 nutrition & dietetics, Visual analogue scale, media_common.quotation_subject, Appetite, Medicine (miscellaneous), 030209 endocrinology & metabolism, Satiation, Eating, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Weight loss, Prospective food consumption, Weight Loss, medicine, Humans, Longitudinal Studies, Obesity, Meals, Satiety Quotient, media_common, 0303 health sciences, Meal, Fullness, Nutrition and Dietetics, Sleep quality, business.industry, Clinical study design, Anthropometry, 3. Good health, Nutrition Assessment, Desire to eat, Energy density, Energy intake, Female, medicine.symptom, business, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, Clinical psychology

الوصف: The satiating efficiency of food has been increasingly quantified using the Satiety Quotient (SQ). The SQ integrates both the energy content of food ingested during a meal and the associated change in appetite sensations. This systematic review examines the available evidence regarding its methodological use and clinical utility. A literature search was conducted in six databases considering studies from 1900 to April 2020 that used SQ in adults, adolescents and children. All study designs were included. From the initial 495 references found, fifty-two were included. Of the studies included, thirty-three were acute studies (twenty-nine in adults and four in adolescents) and nineteen were longitudinal studies in adults. A high methodological heterogeneity in the application of the SQ was observed between studies. Five main utilisations of the SQ were identified: its association with (i) energy intake; (ii) anthropometric variables; (iii) energy expenditure/physical activity; (iv) sleep quality and quantity and (v) to classify individuals by their satiety responsiveness (i.e. low and high satiety phenotypes). Altogether, the studies suggest the SQ as an interesting clinical tool regarding the satiety responsiveness to a meal and its changes in responses to weight loss in adults. The SQ might be a reliable clinical indicator in adults when it comes to both obesity prevention and treatment. There is a need for more standardised use of the SQ in addition to further studies to investigate its validity in different contexts and populations, especially among children and adolescents.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b04774f7e5f6e0121fa40af95418ed3bTest
https://doi.org/10.1017/s0007114520002457Test

المؤلفون: Jean-Philippe Drouin-Chartier, Alain Veilleux, Catherine Lalande, André J. Tremblay, Patrick Couture

المصدر: Diabetology & Metabolic Syndrome
Diabetology & Metabolic Syndrome, Vol 12, Iss 1, Pp 1-11 (2020)

مصطلحات موضوعية: 0301 basic medicine, medicine.medical_specialty, Enterocyte, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, 030209 endocrinology & metabolism, Type 2 diabetes, 03 medical and health sciences, I-FABP, 0302 clinical medicine, Insulin resistance, Diabetes mellitus, Internal medicine, Internal Medicine, medicine, Glucose homeostasis, lcsh:RC620-627, Adiposity, business.industry, Research, Insulin, Small intestine, medicine.disease, lcsh:Nutritional diseases. Deficiency diseases, 030104 developmental biology, medicine.anatomical_structure, Endocrinology, Citrulline, business, Homeostasis

الوصف: Background Evidence suggests that pathophysiological conditions such as obesity and type 2 diabetes (T2D) are associated with morphologic and metabolic alterations in the small intestinal mucosa. Exploring these alterations generally requires invasive methods, limiting data acquisition to subjects with enteropathies or undergoing bariatric surgery. We aimed to evaluate small intestine epithelial cell homeostasis in a cohort of men covering a wide range of adiposity and glucose homoeostasis statuses. Methods Plasma levels of citrulline, a biomarker of enterocyte mass, and I-FABP, a biomarker of enterocyte death, were measured by UHPLC‑MS and ELISA in 154 nondiabetic men and 67 men with a T2D diagnosis. Results Plasma citrulline was significantly reduced in men with insulin resistance and T2D compared to insulin sensitive men. Decreased citrulline levels were, however, not observed in men with uncontrolled metabolic parameters during T2D. Plasma I-FABP was significantly higher in men with T2D, especially in presence of uncontrolled glycemic and lipid profile parameters. Integration of both parameters, which estimate enterocyte turnover, was associated with glucose homeostasis as well as with T2D diagnosis. Differences in biomarkers levels were independent of age and BMI and glucose filtration rates. Conclusions Our study supports a decreased functional enterocyte mass and an increased enterocyte death rate in presence of metabolic alterations but emphasizes that epithelial cell homeostasis is especially altered in presence of severe insulin resistance and T2D. The marked changes in small intestine cellularity observed in obesity and diabetes are thus suggested to be part of gut dysfunctions, mainly at an advanced stage of the disease.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77d3b1af5c219b9ce11c656a722e158eTest
https://doi.org/10.1186/s13098-020-00530-6Test

المؤلفون: Jean Bergeron, Patrick Couture, Benoît Lamarche, André J. Tremblay, Jean-Philippe Drouin-Chartier

المصدر: Atherosclerosis. 270:26-32

مصطلحات موضوعية: Male, Time Factors, Familial hypercholesterolemia, 030204 cardiovascular system & hematology, Compound heterozygosity, chemistry.chemical_compound, 0302 clinical medicine, Longitudinal Studies, 030212 general & internal medicine, Hyperlipoproteinemia Type II, biology, Dextran Sulfate, Homozygote, Lipoprotein(a), Heparin, Middle Aged, Phenotype, Treatment Outcome, Quartile, Blood Component Removal, Female, lipids (amino acids, peptides, and proteins), Cardiology and Cardiovascular Medicine, medicine.drug, Adult, medicine.medical_specialty, Young Adult, 03 medical and health sciences, Internal medicine, medicine, Humans, Genetic Predisposition to Disease, Triglycerides, Retrospective Studies, Triglyceride, business.industry, Cholesterol, LDL, medicine.disease, Endocrinology, Receptors, LDL, chemistry, Mutation, biology.protein, Adsorption, business, Biomarkers, Lipoprotein

الوصف: Background and aims Maximizing the acute reduction of LDL-cholesterol (C) and lipoprotein (a) (Lp(a)) concentrations in patients with homozygous familial hypercholesterolemia (HoFH) is the main goal of lipoprotein apheresis (LA). The objective of this study was to examine how the pre-LA serum TG concentrations influence the efficacy of LA to acutely reduce LDL-C and Lp(a) concentrations in HoFH patients. Methods Data from 1761 LA treatments of HoFH patients (n = 10) and compound heterozygous patients (n = 5) collected between 2008 and 2016 were analyzed. These data included the pre- and post-LA concentrations of LDL-C, TGs and Lp(a); volume of filtered plasma; type of LA system used (dextran sulfate adsorption (DSA) or heparin-induced extracorporeal LDL precipitation (HELP)); and interval between treatments. Results A significant association between the pre-LA TG concentrations and acute LA-induced reduction in LDL-C, modified by the type of LA system used, was observed (p pre-LA TG quartile*LA system = .04). Using the DSA system, the acute reduction of the LDL-C concentrations was attenuated by 3.9% when the pre-LA TG concentrations were >2.09 mmol/L vs. ≤0.93 mmol/L (highest vs. lowest quartiles: −59.4% vs. −63.3%, p = .007). Using the HELP system, no significant difference was observed in the reduction of LDL-C between the highest and the lowest quartiles of serum TGs (−65.8% vs. −66.4%, p = .9). No association was observed between pre-LA TG concentrations and acute LA-induced decrease in Lp(a) (p = .2). Conclusions The efficacy of LA is inversely associated with pre-LA TG concentrations in HoFH patients who used the DSA system instead of the HELP system.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b201e410e32471b690d8ce833f350eeTest
https://doi.org/10.1016Test/j.atherosclerosis.2018.01.005

المؤلفون: Jabbour G, Mélanie Henderson, André J. Tremblay, Marie-Eve Mathieu

المصدر: Biology of Sport, Vol 34, Iss 1, Pp 71-76 (2016)
Biology of Sport

مصطلحات موضوعية: medicine.medical_specialty, Energy transfer, Physical activity, Physical Therapy, Sports Therapy and Rehabilitation, Growth, Body weight, Physiology (medical), Medicine, Orthopedics and Sports Medicine, Moderate-to-vigorous physical activity, Power output, lcsh:Sports medicine, Total energy, lcsh:QH301-705.5, Original Paper, Watt, business.industry, Follow-up, Mechanical output, lcsh:Biology (General), Cohort, Exercise intensity, Physical therapy, lcsh:RC1200-1245, business, Demography

الوصف: Net mechanical efficiency (MEnet), which reflects the body’s ability to transfer energy above resting levels in external work, is similar in young children regardless of their body weights. However, it is unclear whether MEnet remains stable during growth and maturation. We sought to determine whether net mechanical efficiency (MEnet) changes over a period of 3 years in children and to identify the factors associated with possible changes. A total of 169 children participating in the QUALITY (Quebec Adipose and Lifestyle InvesTigation in Youth) cohort completed an incremental cycling test, resulting in the same maximal power output during both visits. For MEnet, resting energy consumption was subtracted from total energy consumption at each exercise stage. Physical activity was measured using an accelerometer worn for 7 days. Participants were measured at year one and again two years later. MEnet did not differ across the visits at the 25, 50 and 75 watt stages. However, the participants exhibited lower MEnet values at follow-up for the 100 and 125 W stages (23(3) vs. 20(1)%; 25(4) vs. 20(2)%; p

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bf51550601f0b3de8a95ea43866431cTest
https://doi.org/10.5114/biolsport.2017.63736Test

المؤلفون: Jean-Philippe Drouin-Chartier, Benoît Lamarche, Marie-Claude Lépine, Patrick Couture, André J. Tremblay, Valéry Lemelin

المصدر: Diabetes, Obesity and Metabolism. 18:1226-1235

مصطلحات موضوعية: 0301 basic medicine, medicine.medical_specialty, business.industry, Endocrinology, Diabetes and Metabolism, PCSK9, 030204 cardiovascular system & hematology, medicine.disease, Small intestine, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Endocrinology, Real-time polymerase chain reaction, Insulin resistance, medicine.anatomical_structure, Ezetimibe, Internal medicine, Gene expression, LDL receptor, Internal Medicine, Intestinal cholesterol absorption, medicine, business, medicine.drug

الوصف: Aim To gain further insight into intestinal cholesterol homeostasis in dyslipidaemic men with insulin resistance (IR) by examining the impact of treatment with ezetimibe on the expression of key genes involved in cholesterol synthesis and LDL receptor (R)-mediated uptake of lipoproteins. Methods A total of 25 men with dyslipidaemia and IR were recruited to participate in this double-blind, randomized, crossover, placebo-controlled trial. Participants received 10 mg/day ezetimibe or placebo for periods of 12 weeks each. Intestinal gene expression was measured by quantitative PCR in duodenal biopsy samples collected by gastroduodenoscopy at the end of each treatment. Results A total of 20 participants completed the protocol. Treatment with ezetimibe significantly increased intestinal LDLR (+16.2%; P = .01), 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoAR; +14.0%; P = .04) and acetyl-Coenzyme A acetyltransferase 2 (ACAT-2) mRNA expression (+12.5%; P = .03). Changes in sterol regulatory element-binding transcription factor 2 (SREBP-2) expression were significantly correlated with changes in HMG-CoAR (r = 0.55; P

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::0f861547b914287a79af7d3b5e943b1dTest
https://doi.org/10.1111/dom.12749Test

المؤلفون: Maud Miguet, Yves Boirie, Marie-Eve Mathieu, P. M. Genin, Marwa Khammassi, Graham Finlayson, André J. Tremblay, John E. Blundell, Alicia Fillon, Martine Duclos, Lore Metz, B. Pereira, Vicky Drapeau, David Thivel

المساهمون: EA 3533, Laboratoire des Adaptations Métaboliques à l’Exercice en conditions Physiologiques et Pathologiques (AME2P), Université Clermont Auvergne (UCA), Appetite Control and Energy Balance Research Group, University of Leeds, Centre de SSR Nutrition-Obésité UGECAM, DRCI, Biostatistiques, CHU Clermont-Ferrand, Unité de Nutrition Humaine - Clermont Auvergne (UNH), Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne (UCA), Nutrition clinique, Centre Hospitalier Universitaire Gabriel Montpied, CRNH Auvergne, Médecine du sport et exploration fonctionnelle, CHU Gabriel Montpied [Clermont-Ferrand], Institute of Nutrition and Functional Foods INAF, Université Laval, School of kinesiology and Physical Activity Sciences, Université de Montréal (UdeM), Laboratoire des Adaptations Métaboliques à l'Exercice en Conditions Physiologiques et Pathologiques (AME2P), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-UFR Sciences et Techniques des Activités Physiques et Sportives - Clermont-Auvergne (UFR STAPS - UCA), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Centre de Recherche en Nutrition Humaine Auvergne [CHU Clermont-Ferrand] (CRNH A), Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), Unité de Nutrition Humaine (UNH), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), National French University Institute (IUF)

المصدر: Appetite
Appetite, Elsevier, 2020, 145, ⟨10.1016/j.appet.2019.104500⟩
Appetite, 2020, 145, ⟨10.1016/j.appet.2019.104500⟩

مصطلحات موضوعية: Male, 0301 basic medicine, medicine.medical_specialty, Intensity, media_common.quotation_subject, Appetite, 030209 endocrinology & metabolism, Satiation, Affect (psychology), Food Preferences, Young Adult, 03 medical and health sciences, Oxygen Consumption, 0302 clinical medicine, Reward, Satiety quotient, Surveys and Questionnaires, [SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], Humans, Medicine, Young adult, Exercise, General Psychology, Aerobic capacity, media_common, 2. Zero hunger, Meal, 030109 nutrition & dietetics, Nutrition and Dietetics, business.industry, digestive, oral, and skin physiology, Food reward, VO2 max, Anthropometry, Food, Body Composition, Physical therapy, Female, Energy Intake, business, human activities, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, Body mass index

الوصف: To compare the effect of iso-caloric low and high intensity exercises on Satiety Quotient and Food Reward in response to a fixed meal in healthy young adults. Anthropometric measurements, body composition (BIA), aerobic capacity (VO2 max) and food preferences were assessed in 19 healthy normal-weight young adults (21 +/- 0.5 years old, 10 men). They randomly completed 3 experimental sessions: i) control session without exercise (CON); ii) High Intensity exercise session (HIE); iii) Low intensity exercise session (LIE). Thirty minutes after exercise or rest, then received a fixed lunch. Food reward (Leeds Food Preference Questionnaire) was assessed before and after the meal. Appetite sensations were assessed at regular intervals, SQ was calculated from the lunch meal and self-reported food intake was collected for the rest of the day. Mean body weight was 66.7 +/- 9.2 kg, body mass index was 22.3 +/- 2.9 kg/m2 and FM% was 18.7 +/- 6.8%. Appetite feelings did not differ between conditions and were not affected by exercise. SQ for satiety was not different between conditions. SQ hunger on CON was significantly higher than on LIE and HIE (p= 0.05) with no difference between exercise conditions. SQ for desire to eat was significantly higher on CON versus HIE (p= 0.01) with no differences between CON and LIE and between exercise sessions. SQ PFC was significantly lower on HIE compared with CON (p= 0.02) with no differences between LIE and CON and between LIE and HIE. Food reward was not significantly different between the three condition as well as self-reported total food and macronutrient intake for the rest of the days. Acute exercise, depending on its intensity, might affect the satiating response to food intake in healthy adults, without altering food reward.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64800d885ad2009b41d489713b0d98a6Test
https://doi.org/10.1016Test/j.appet.2019.104500

المؤلفون: Seth S. Martin, Allan D. Sniderman, André J. Tremblay, George Thanassoulis, Jacqueline de Graaf, Patrick Couture

المصدر: Journal of Clinical Lipidology, 12, 6, pp. 1383-1389
Journal of Clinical Lipidology, 12, 1383-1389

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Very low-density lipoprotein, Percentile, Apolipoprotein B, Adolescent, Endocrinology, Diabetes and Metabolism, Lipoproteins, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], 030204 cardiovascular system & hematology, digestive system, Diagnosis, Differential, 03 medical and health sciences, chemistry.chemical_compound, Young Adult, 0302 clinical medicine, Internal medicine, Hyperlipoproteinemia Type III, Internal Medicine, medicine, Humans, 030212 general & internal medicine, Hypertriglyceridemia, Nutrition and Dietetics, biology, Triglyceride, business.industry, Cholesterol, nutritional and metabolic diseases, Middle Aged, medicine.disease, Endocrinology, chemistry, biology.protein, lipids (amino acids, peptides, and proteins), Female, Cardiology and Cardiovascular Medicine, business, Chylomicron, Lipoprotein

الوصف: Item does not contain fulltext BACKGROUND: Type III hyperlipoproteinemia is a highly atherogenic dyslipoproteinemia characterized by hypercholesterolemia and hypertriglyceridemia due to markedly increased numbers of cholesterol-enriched chylomicron and very-low-density lipoprotein (VLDL) remnant lipoprotein particles. Type III can be distinguished from mixed hyperlipidemia based on a simple diagnostic algorithm, which involves total cholesterol, triglycerides, and apolipoprotein B (apoB). However, apoB is not measured routinely. OBJECTIVE: The objective of the present study was to determine if patients with type III could be distinguished from mixed hyperlipidemia based on lipoprotein lipids. METHODS: Classification was based first on total cholesterol and triglyceride and then on the apoB diagnostic algorithm using apoB plus total cholesterol plus triglycerides, and validated by sequential ultracentrifugation. Four hundred and forty normals, 637 patients with hypertriglyceridemia, and 714 with hypertriglyceridemia and hypercholesterolemia were studied. Plasma lipoproteins were separated by sequential ultracentrifugation and heparin-manganese precipitation. Cholesterol, triglyceride, and apoB were measured in plasma and isolated lipoprotein fractions. RESULTS: Of the 1351 patients with hypertriglyceridemia, 49 had type III hyperlipoproteinemia, as diagnosed by the apoB algorithm and validated by ultracentrifugation. Plasma triglycerides were higher in the type III subjects: 4.16 mmol/L (3.35-6.08, 25th-75th percentile), but there was considerable overlap with the hypertriglyceridemic subjects 2.65 mmol/L (1.91-4.20, 25th-75th percentile) and the combined hyperlipidemic subjects 3.02 mmol/L (2.07-5.32, 25th-75th percentile). Similarly, total cholesterol was 4.79 mmol/L (4.31-5.58, 25th-75th percentile) for type III vs 5.5 mmol/L (4.64-5.78, 25th-75th percentile) and 7.02 mmol/L (6.39-7.96, 25th-75th percentile), respectively. By contrast, as identified by the apoB algorithm, the VLDL-C/TG, VLDL-C/VLDL-TG, VLDL-C/VLDL apoB, and VLDL apoB/LDL apoB ratios were all higher in type III than in the other hypertriglyceridemic dyslipoproteinemias with the exception of type V as diagnosed by the apoB algorithm. CONCLUSION: Cholesterol and triglycerides cannot reliably distinguish type III hyperlipoproteinemia from mixed hyperlipidemia. Adding apoB and applying the apoB algorithm makes reliable diagnosis possible and easy. However, unless apoB is introduced into routine clinical care, type III hyperlipoproteinemia will often not be recognized. Given the cardiovascular risk associated with type III and its responsiveness to treatment, this should not be acceptable.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1702319ef1eb8914eafff7b5f6ad710fTest
https://pubmed.ncbi.nlm.nih.gov/30318453Test

المؤلفون: Jean Bergeron, Jean-Philippe Drouin-Chartier, André J. Tremblay, Patrick Couture, Benoît Lamarche

المصدر: Circulation. 136(9)

مصطلحات موضوعية: 0301 basic medicine, Adult, Male, medicine.medical_specialty, Familial hypercholesterolemia, 030204 cardiovascular system & hematology, Hyperlipoproteinemia Type II, 03 medical and health sciences, chemistry.chemical_compound, Young Adult, 0302 clinical medicine, Physiology (medical), Internal medicine, Genotype, medicine, Humans, Genetic Predisposition to Disease, Longitudinal Studies, Receptor, Retrospective Studies, Cholesterol, business.industry, Homozygote, Cholesterol, LDL, Middle Aged, medicine.disease, 030104 developmental biology, Apheresis, Endocrinology, Phenotype, Treatment Outcome, chemistry, Receptors, LDL, LDL receptor, Mutation, Blood Component Removal, lipids (amino acids, peptides, and proteins), Female, Cardiology and Cardiovascular Medicine, business, Lipoprotein apheresis, Biomarkers, Lipoprotein, Lipoprotein(a)

الوصف: In homozygous familial hypercholesterolemia (HoFH) caused by mutations in the low-density lipoprotein (LDL) receptor ( LDLR ) gene, patients with 2 receptor-negative mutations have higher cholesterol concentrations and coronary heart disease risk than patients with double receptor-defective mutations.1 Pharmacological treatment is insufficient to achieve an efficient reduction in LDL-cholesterol (C) or lipoprotein (a) (Lp(a)) concentrations in patients with HoFH, and repetitive long-term lipoprotein apheresis (LA) remains the gold-standard therapy. LA induces an acute decrease in LDL-C and Lp(a) concentrations, which is then followed by a rebound in the following days. The rebound after LA constitutes a major determinant of LA efficacy because it directly affects the average concentrations between treatments, considered the best estimate of the physiological effects of long-term LA.2 However, our understanding of the determinants of rebound after treatment in LDL-C and Lp(a) is limited.2 This study aimed to determine the extent to which the LDLR genotype modulates the rebound after LA in LDL-C and Lp(a) concentrations among patients with HoFH. We hypothesized that the rebound in LDL-C and Lp(a) concentrations is greater among patients with receptor-negative HoFH than among patients with receptor-defective HoFH. Data on all consecutive LA treatments performed between August 2008 and February 2016 among patients with HoFH with genetically defined defective/defective LDLR mutations (n=3), negative/negative LDLR mutations (n=8), and defective/negative LDLR mutations (n=4) treated at the CHU de Quebec-Universite Laval were collected. For each patient, the compiled data included: (1) date of LA, (2) cumulative number of LA treatments received, (3) interval between LA treatments, (4) LA system used, (5) volume of filtered plasma per treatment, (6) duration of treatments, (7) lipoprotein concentrations before and after LA, and (8) cumulative interval since the first compiled LA treatment. Data on …

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::898b6c43a3f54c1a2798d91d65023d1cTest
https://pubmed.ncbi.nlm.nih.gov/28847800Test

المؤلفون: Benoît Lamarche, André J. Tremblay, Nathalie Laflamme, Jean Bergeron, Patrick Couture, Jean-Philippe Drouin-Chartier

المصدر: Journal of clinical apheresis. 33(1)

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Microarray, Familial hypercholesterolemia, 030204 cardiovascular system & hematology, Hyperlipoproteinemia Type II, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, B-Cell Lymphoma 3 Protein, Internal medicine, Proto-Oncogene Proteins, medicine, Humans, RNA, Messenger, Whole blood, Cholesterol, business.industry, Microarray analysis techniques, Extracorporeal circulation, Dextran Sulfate, Homozygote, Hematology, General Medicine, Cholesterol, LDL, Middle Aged, medicine.disease, Lymphoma, body regions, ErbB Receptors, Endocrinology, chemistry, Gene Expression Regulation, Blood Component Removal, Female, Adsorption, business, 030215 immunology, Lipoprotein, Lipoprotein(a), Transcription Factors

الوصف: Lipoprotein apheresis (LA) with dextran sulfate adsorption (DSA) is a reliable method to decrease LDL-cholesterol (C) concentrations in patients with homozygous familial hypercholesterolemia (HoFH). The objective of the present study was to investigate the impact of LA with DSA on the mRNA expression of genes associated with cardiovascular health in the whole blood of HoFH patients. Blood samples were collected before and after LA treatment with DSA in 9 HoFH patients. Microarray analyses were performed to measure the whole blood expression of >30 000 annotated genes pre- and post-LA. Concomitant reductions in LDL-C (median -73.8%, range: -55.9 to -82.0, P = .0001) and lipoprotein (a) concentrations (median -74.1%, range -65.6 to -84.1, P = .003) were induced with LA treatment. LA with DSA did not impact the whole blood mRNA expression of most key genes involved in cardiovascular health, including those associated with cholesterol, fatty acid and lipoprotein metabolism. However, LA with DSA significantly upregulated the whole blood expression of early growth response protein (EGR)1 (1.94-fold, P = .02), EGR3 (1.56-fold, P = .0008) and B-cell lymphoma 3-encoded protein (BCL3; 1.25-fold, P = .03). In conclusion, this study demonstrated that a single LA treatment with DSA has very limited impact on the whole blood expression of a broad spectrum of genes associated with cardiovascular health. Our results suggest that contact between blood cells and the primary membrane or extracorporeal circulation could upregulate the expression of EGR1, EGR3, BCL3, and MMP9 in blood cells.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d48619e00f78edda517136b2b59c45b6Test
https://pubmed.ncbi.nlm.nih.gov/28712132Test

المؤلفون: Jean-Philippe Drouin-Chartier, Jean-Charles Hogue, Patrick Couture, Jean Bergeron, André J. Tremblay, Benoît Lamarche

المصدر: Lipids in Health and Disease
Lipids in Health and Disease, Vol 16, Iss 1, Pp 1-8 (2017)

مصطلحات موضوعية: 0301 basic medicine, Apolipoprotein B-48, Adult, Male, medicine.medical_specialty, Apolipoprotein B, Adolescent, Clinical chemistry, Endocrinology, Diabetes and Metabolism, Lipoproteins, Clinical Biochemistry, Familial hypercholesterolemia, Clinical nutrition, Hyperlipoproteinemia Type II, PCSK9, 03 medical and health sciences, Young Adult, Endocrinology, Internal medicine, medicine, Humans, Point Mutation, Child, lcsh:RC620-627, biology, business.industry, Research, Biochemistry (medical), Middle Aged, medicine.disease, Atherosclerosis, lcsh:Nutritional diseases. Deficiency diseases, 030104 developmental biology, LDL receptor, Apolipoprotein B-100, biology.protein, lipids (amino acids, peptides, and proteins), Female, Proprotein Convertase 9, business, Lipidology

الوصف: Previous studies have reported high plasma concentrations of both intestinal apolipoprotein (apo) B-48-containing lipoproteins and PCSK9 in subjects with familial hypercholesterolemia (FH). However, the extent to which LDL receptor deficiency and PCSK9 levels influence plasma apoB-48 concentrations in humans remains to be fully characterized. The objective of the study was to assess the independent association between FH, PCSK9 concentrations and plasma apoB-48 levels in a large cohort of genetically defined FH heterozygotes (HeFH) and homozygotes (HoFH). A total of 118 HeFH, 6 HoFH, and 117 controls were included in the study. Plasma PCSK9 and apoB-48 concentrations were measured in the fasting state. Plasma PCSK9 and apoB-48 levels were higher in FH subjects compared with controls (PCSK9: HoFH: 642.6 ± 246.9 vs. HeFH: 324.9 ± 119.8 vs. controls: 194.5 ± 65.9 ng/mL, P

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42ea963de7cc2943e6a5f125c2ea3fedTest
https://pubmed.ncbi.nlm.nih.gov/28619117Test